Oncology and Hematology - Global Oncology Academy

49-64 of 790

Real-World Outcomes with Axatilimab in cGVHD
Real-World Outcomes with Axatilimab in cGVHD
Project Oncology®
Real-World Outcomes with Axatilimab in cGVHD
Brian P. McDonough, MD, FAAFP; Hana Safah, MD
- Brian P. McDonough, MD, FAAFP
- Hana Safah, MD
Axatilimab’s Impact on cGVHD and Associated BOS
Axatilimab’s Impact on cGVHD and Associated BOS
Project Oncology®
Axatilimab’s Impact on cGVHD and Associated BOS
Charles Turck, PharmD, BCPS, BCCCP; Amandeep Salhotra, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Amandeep Salhotra, MD
CME/CE Virtual Event
Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care
Multiple dates available
0.75 credits
The Art of Treatment Sequencing in Advanced Urothelial Carcinoma
The Art of Treatment Sequencing in Advanced Urothelial Carcinoma
Project Oncology®
The Art of Treatment Sequencing in Advanced Urothelial Carcinoma
Guru P. Sonpavde, MD
- Guru P. Sonpavde, MD
First-Line Treatment Considerations in Advanced Urothelial Carcinoma
First-Line Treatment Considerations in Advanced Urothelial Carcinoma
Project Oncology®
First-Line Treatment Considerations in Advanced Urothelial Carcinoma
Guru P. Sonpavde, MD
- Guru P. Sonpavde, MD
Advanced Urothelial Carcinoma: Optimizing Second-Line Care
Advanced Urothelial Carcinoma: Optimizing Second-Line Care
Project Oncology®
Advanced Urothelial Carcinoma: Optimizing Second-Line Care
Guru P. Sonpavde, MD
- Guru P. Sonpavde, MD
Current Approaches to Advanced Urothelial Carcinoma
Current Approaches to Advanced Urothelial Carcinoma
Project Oncology®
Current Approaches to Advanced Urothelial Carcinoma
Guru P. Sonpavde, MD
- Guru P. Sonpavde, MD
Urine RNA Panel Supports Less Invasive Bladder Cancer Surveillance
Urine RNA Panel Supports Less Invasive Bladder Cancer Surveillance
Project Oncology®
Urine RNA Panel Supports Less Invasive Bladder Cancer Surveillance
Can AI Imaging Improve Risk Stratification in Upper Tract Urothelial Carcinoma?
Can AI Imaging Improve Risk Stratification in Upper Tract Urothelial Carcinoma?
Project Oncology®
Can AI Imaging Improve Risk Stratification in Upper Tract Urothelial Carcinoma?
CME/CE In-Person & Virtual Event
The CELMoD Shift: Translating Protein Degradation Science Into Practice-Changing Myeloma Care
December 11, 2026
New Orleans, Louisiana
1.50 credits
Real-World Sacituzumab Govitecan Reinforces Benefit in mTNBC
Real-World Sacituzumab Govitecan Reinforces Benefit in mTNBC
On the Frontlines of Metastatic Breast Cancer
Real-World Sacituzumab Govitecan Reinforces Benefit in mTNBC
Ryan Quigley
- Ryan Quigley
CME/CE Virtual Event
Data Meets Decision: Expert Approaches to Perioperative Immunotherapy in LA HNSCC
Multiple dates available
0.75 credits
MinuteCE®
Beyond Checkpoint Blockade in SCLC: Emerging Antigen Targets and Treatment Strategies Across Disease Stages
Neal Ready, MD, PhD; Ticiana Leal, MD
0.50 credits 4 episodes
- Neal Ready, MD, PhD
- Ticiana Leal, MD
0.50 credits 4 episodes
On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
MinuteCE®
On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
Ticiana Leal, MD
0.50 program credits
- Ticiana Leal, MD
0.50 program credits
Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs
Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs
CME/CE
Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs
Sara A. Hurvitz, MD, FACP; Tiffany Traina, MD
0.50 credits
- Sara A. Hurvitz, MD, FACP
- Tiffany Traina, MD
0.50 credits
The Survival Ceiling in ES-SCLC: Why Checkpoint Blockade Alone Is Not Enough
The Survival Ceiling in ES-SCLC: Why Checkpoint Blockade Alone Is Not Enough
MinuteCE®
The Survival Ceiling in ES-SCLC: Why Checkpoint Blockade Alone Is Not Enough
Neal Ready, MD, PhD
0.50 program credits
- Neal Ready, MD, PhD
0.50 program credits

4/9